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Genetically modiﬁed animals are state of the art in biomedical research as gene therapy is a promising
perspective in the attempt to cure hereditary diseases. Both approaches have in common that modiﬁed
or corrected genetic information must be transferred into cells in general or into particular cell types of
an organism. Here we give an overview of established and emerging methods of transfection and gene
delivery and provide conceptual and technical advantages and drawbacks of their particular use.
Additionally, based on a ﬂow chart, we compiled a rough guideline to choose a gene transfer method
for a particular ﬁeld of application.
 2015 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).Genetically modiﬁed animals are state of the art routine in bio-
medical research as gene therapy is a promising perspective in the
attempt to cure hereditary diseases. Both approaches have in com-
mon that modiﬁed or corrected genetic information must be
inserted into cells in general or into particular cells of an organism.
The DNA needs to be available as a plasmid to be transfected.
However, the topic of this Digest is not about cloning strategies
but focuses on different methods of transfection and gene transfer
and their conceptual application. Transfection can be categorized
into physical, chemical and biological methods. In the history of
gene delivery into cells, initial successful transfection was achieved
with chemical methods.1,2 The calcium phosphate co-precipitation
method was examined by Graham and van der Eb3 in the early
1970s and became a very popular method, which is still used
(see below). An overview of selected transfection and gene-transfer
methods is given in Table 1.
Physical transfection approaches include microinjection,4
optical transfection,5,6 particle guns (ballistic gene delivery),7,8
electroporation,9 sonoporation,10 magnetofection11 and electric
ﬁeld-induced molecular vibration.12 The ﬁrst two examples are
methods where usually only one cell is transfected at a time. The
disadvantage is an ultra low throughput, but the certainty that
the cell of interest is indeed transfected. Therefore methods like
microinjection are popular for gene transfer when only a limited
number of cells are available, like a variant in the creation of trans-
genic animals when the DNA is directly injected into the male pro-
nucleus. After the fusion of the pro-nuclei the diploid zygotenucleus is formed and the zygote is cultivated to the state of the
two-cell embryo.
A particular interesting concept of physical transfection is laser-
mediated transfection. This can be a direct membrane perfora-
tion,13 methods taking advantage of nanoparticles14 or techniques
using wave-guided optical wave guides (WOW).15 The idea of the
latter is to use lTools that can be moved and navigated by the
use of laser beams that are manipulated by programmable diffrac-
tion patterns resulting in so called holographic optical tweezers
(HOT).16 The lTool are designed such that their tip can be brought
in contact with the cell of interest. The energy of laser-generated
photons, which are fed into the tail of the lTool, and that travel
through the intrinsic optical waveguides result in a thermopora-
tion at the tip of the lTool (compare Table 1).
A further advantage is that physical transfection does not
depend on particular chemical or biological cell properties17 and
therefore cells that are difﬁcult to be transfected by other methods
(see below), like cells of the immune system, for example, T-cells,
can be successfully manipulated by physical transfection
approaches. Methods that can be applied to cell suspensions, for
example, electroporation, are particular popular.17
Chemical transfection methods are techniques that catalyze
DNA cross-membrane transport through the use of Ca2+ phos-
phate,18 polycations19 or dendrimers.20
Transfection with Ca2+ phosphate is one of the least expensive
methods and is therefore still applied, whenever large amounts
of cells need to be transfected simultaneously, for example, for
the production (and later puriﬁcation) of particular proteins or
virus (see below). The method is effective with many different cul-
tured cell types.
Table 1
Overview of selected popular transfection and transduction methods
Method Principle Scheme Advantages Disadvantages Field of application
Microinjection4
Direct injection of the
genetic information into the
nucleus of the target cell
under visual (microscopic)
control
Most direct transfection;
after initial training high
yield of success
Tedious, very
limited number of
transfected cells,
more difﬁcult on
small cells
Making transgenic animals,
studying RNA trafﬁcking,
immuno-cytochemistry
lTool based
thermoporation15
lTools can be manipulated
by laser beams and
thermoperforate the cell by
laser energy delivered to
the tail of the lTool and
wave-guided to its tip
Versatile tool with high
potential for special
requirements
Technical
demanding;
currently under
development and
only available in
specialized labs
To be determined
Electroporation9,10,17
Application of changing
electrical potentials to
induce the formation of
pores in the cell membrane
Established and effective
method for otherwise hard
to transfect cells in
suspension and to some
extend in tissue; often used
for primary isolated cells
Needs speciﬁc
adaptation and
optimization of
parameters for
particular cell
types; tendency for
high level of
damaged cells
Wide range, whenever a
limited cell viability is
tolerable; local transfection
in vivo with specialized
electrodes (needles)
Calcium
phosphate3,18
After adsorption of the
DNA, calcium phosphate
coprecipitates to the cell
surface and is taken up by
phagocytosis
Cheap and easy to perform;
large amounts of cells can
be transfected
Relatively low
transfection rate;
primary cells and
cells in suspension
can hardly be
transfected
Transfection for protein
puriﬁcation and similar
approaches
Polycations19
The polycations form
complexes with the
polyanionic DNA molecules
and these complexes are
taken up by phagocytosis
Large size of DNA can be
transfected and it should be
useful in gene therapy
when viral gene delivery is
not useful because of the
immune response
Sometimes poor
efﬁciency;
cytotoxicity for
sensitive cells and
high mutation rate
of the DNA
Gene therapy together with
drug delivery
Lipofection21–24
Vesicles of cationic lipids
bind to DNA and positively
charged complexes bind to
the cell surface (negatively
charged silica acid residues)
followed by uptake into the
cells
Simple and fast procedure
with high reproducibility
Not suitable for
most primary
isolated cells
Most popular method in
cell biology and related
research ﬁelds
Dendrimers20
Positively charged
dendrimers bind with the
negatively charged
phosphates of the DNA
molecule (electrostatic) and
the DNA–dendrimer
complexes with a positive
net charge are taken up by
the cell
No or low cytotoxicity; high
efﬁciency in numerous cell
lines
Not suitable for
most primary
isolated cells
Often applied in
combination with
lipofection, therefore
similar ﬁeld of application
Receptor mediation7
Utilises endocytosis for
uptake of proteins, DNA is
bound to the ligand of the
target receptor via a DNA
binding moiety (like poly-L-
lysin)
Cell speciﬁc transfection,
very low cytotoxicity and
reapplication possible
Effective
transfection only
possible with cells
carrying a high
density of the
receptor
Cell therapy
Virus30
Genetic information is
incorporated into a virus
and when the virus infects
the cell, the protein of
interest is transduced in the
infected cell
Broad selection of different
virus types; high speciﬁcity
by tissue-speciﬁc
promoters and tissue
tropism (only AAV); fast
expression (Semliki-Forrest
virus); long constant
expression levels
(especially Lentivirus);
genome integration (only
AAV and Lentivirus)
Limited size of DNA;
may induce
cytopathic effects
Can be used for almost all
cell types, except cells of
the immune system;
preferentially used for
terminally differentiated
cells like neurons and
cardiomyocytes; broad
application in vivo
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Table 1 (continued)
Method Principle Scheme Advantages Disadvantages Field of application
Cell penetrating
peptides53
Design of synthetic
peptides that mimic
recognition, binding or
membrane disruption
aspects of viral proteins
No cell speciﬁcity
Difﬁcult targeting
within an organism
Often used as complement
for other non-viral
transfection method
References noted next to the method refer to recent reviews or major contributions.
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Figure 1. Example of an expression (of the genetically encoded Ca2+ indicator
YC3.6) after AAV-mediated gene transfer (6  1012 vector genomes per ml). (A)
Typical Western blots (anti-GFP monoclonal mouse antibody, Roche, Germany)
from mouse hearts at different time periods after neonatal jugular vein injection.
(B) White light (top) and ﬂuorescence image (bottom) of a cut-open mouse heart
16 weeks after AAV-injection. (C) Single cell expression analysis 16 weeks after
AAV-injection by ﬂuorescence imaging of isolated cardiomyocytes of the left
atrium. The ﬂuorescent protein is depicted in green, while the membrane staining
with CellMask Deep Red is shown in red. The white rectangle indicates the enlarged
region replotted in the right bottom corner. (D) Representative histogram of the
ﬂuorescence intensity distribution of cells as exempliﬁed in (C). This ﬁgure is
reproduced from Kaestner et al.30, with permission from Wolters Kluwer.
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cal method21 and sometimes as a biological technique.22 In any
case it is a popular transfection method,23 which when compared
with (other) chemical methods leads to a 5- to 100-fold increased
transfection rate.24 Lipofection is well suited in cell lines and many
primary neonatal cells. It is based on cationic lipids, which
consist of a positively charged head group and one or two hydro-
carbon chains. The head group interacts with the negatively
charged phosphate backbone of the nucleic acids, thus forming a
compact structure. Together with additional neutral helper lipids
the transfection complex builds uni-lamellar, liposomal structures
with a positive surface charge in aqueous solutions. The interaction
with the cell membrane is mediated by this positive charge of the
liposomes.
Numerous cationic lipids have been synthesized, including
monovalent and polyvalent cationic lipids, cholesterol derivatives
or guanidine-containing compounds, some of them being commer-
cially available, such as Lipofectamine (or Lipofectamine 2000), a
3:1 (wt/wt) formulation of the polycationic lipid 2,3-dioleoyloxy-
N-(2(sperminecarboxamino)ethyl)-N,N-dimethyl-1-propan-amini-
um triﬂuoroacetate (DOSPA) and the neutral lipid dioleoyl phos-
phatidylethanolamine (DOPE).25 Generally speaking, the cationic
lipids have three segments: a DNA-interacting headgroup with a
net positive charge in physiological conditions or at lower pH such
as found in the endosome environment; a hydrophobic lipid
anchor group such as cholesterol or fatty acid chains of
various lengths and unsaturation states; and a linker group that
binds the polar group to the lipidic moiety. The positively charged
polar groups are of varying types, including: quaternary ammo-
nium ions, polycations such as spermine, or cationic polymeric
compounds such as polyethylenimine, poly-lysine or their
derivatives.
Lipofectamine (Life Technologies), FuGene 6 (Promega) or
Nanojuice (Merck Millipore) are examples of commercially avail-
able transfection formulations or kits, which are commonly used
in biomedical research to transfect cell lines. Somewhat prob-
lematic is the fact that the user often does not know the real
(chemical content) of this composition and the companies are
not willing to provide them even when directly asked. For
Nanojuice, at least, we know that it is a mixture of polycationic
lipids and dendrimers, whereas FuGene 6 just contains ‘lipids
and other components’.26 Only indirect information, like the
history of an US-patent27 and a court case28 about infringement
of that patent, supports the speculation that FuGene contains
histones.
However, DNA transfer by Lipofection is insufﬁcient in most ter-
minally-differentiated primary cells such as adult cardiac myo-
cytes.29,30 Then a ‘real’ biological transfection method such as viral
gene transfer is the transduction method of choice.31–33 In this con-
text, the integration of the indicator DNA into the viral genome can
be challenging.However, viral transduction canbe performed in iso-
lated cells or even in vivo.30
Popular viral systems for transduction include the Semliki-Forest
virus,31 lentivirus,34 and adenovirus.35Employment of the Semliki-Forest virus leads to a very rapid
expression within a very few hours. By contrast, lentiviral gene
transfer requires approximately one week reaching detectable
levels but typically expression is sustained for several months.
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packaging system are supposed to perform better.36 When using
gene transfer with adenoviruses, expression of the genetically
encoded proteins reaches detectable levels within 24 h.37,38 Adeno-
virus-mediated expression is rather stable over the time course of
at least one week, and adverse effects caused by the viral transduc-
tion or induced gene expression during that period are usually not
observed.39,40
Therefore, adenovirus-mediated gene transfer appears to be the
most suitable method for the expression of proteins in cultured
primary cells, which show low lipofection transfection rates. Alter-
natively, Herpes virus-mediated transduction has been success-
fully used to express proteins in primary cell cultures.41 For
in vivo investigations or gene therapy, the transduction and
expression of the gene of interest must be performed not only in
isolated cells but also in the living organism. For experimental
approaches the production and breeding of transgenic animal lines
are a serious undertaking that requires a lot of time, which might
be a serious limitation. An alternative approach for tissue speciﬁc
expression of the gene of interest is to transduce the gene of inter-
est into individual animals, again with the help of a viral vector.
Vectors can be applied directly to the tissue of interest by local
injection or via the vascular system. While direct injections may
lead to a patchy transduction pattern, transvascular or approaches
employing systemic application have the advantage of a more
homogeneous transduction. However, they face additional obsta-
cles such as neutralizing antibodies, binding to plasma proteins
in the circulation, clearance in the liver and ineffective passageFigure 2. Flow chart of a guideline for selecting a method for gene transfer into eukaryoti
they represent an approach to facilitate decision-making but cannot be regarded as anthrough the vascular wall.42 Furthermore, transduction efﬁciency
depends on successful uptake into the cells of destination. Finally,
sustained expression of the transgene depends on the ability of the
vector to prevent clearance of its vector genome from the cell, and
the lack of an immune response against vector epitopes.
Although there are reports of adenovirus-mediated gene silenc-
ing in vivo,43 expression is usually restricted when injected intra-
venously most likely due to the strong immune responses of the
animals against the adenoviral capsid,44 triggering/evoking an
innate immune response against the vector that rapidly cleared
the adenoviral vector. The low number of reports with adenovi-
rus-mediated gene transfer in vivo appears to support this notion.
A method that circumvents the immune response is gene paint-
ing,45 in which virus suspensions are mixed with trypsin and
directly applied to the organ.46,47 However, depending on the
organ this may require a serious surgery which limits usability
and popularity. Therefore, many researchers have focused on
adeno-associated viruses (AAVs) as an alternative approach for
gene delivery.32 AAV is a non-pathogenic parvovirus that enters
the target cell via receptor-mediated endocytosis. Its low immuno-
genicity enables a sustained gene transfer.42 Certain naturally
occurring AAV serotypes such as serotype 9 vectors resulted in uni-
form and extensive cardiac targeting after intravenous injections.48
However, further modiﬁcations of the AAV-vector surface (edu-
cated guess or library-based approaches) could extend the tropism
of gene transfer, for example, to vessels or increase speciﬁcity.
Since AAV vectors enable a highly efﬁcient transduction with lim-
ited target tissue speciﬁcity expression in the tissue of choice canc cells. The criteria are based on the experience and the judgment of the authors, and
inclusive method.
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priate microRNA-target site into the AAV-genome.49
The role of a tissue-speciﬁc promoter is increasingly acknowl-
edged in both, the development of gene therapy and the biomedi-
cal research.50 Figure 1 provides a representative recent example
for an in vivo gene transfer towards the expression of the Ca2+ sen-
sor YC3.651 in cardiac myocytes under control of a cytomegalovirus
(CMV)-enhanced myosin light chain 2v promoter after transduc-
tion of neonatal mice with AAV serotype 9 vector.
With the success of viral mediated gen transfer, the relationship
between structure and function of proteins responsible for these
activities lead to studies with synthetic peptides that mimic recog-
nition, binding, or membrane disruption aspects of the viral pro-
teins.52 These developments resulted in cell penetrating peptides,
also known as protein transduction domains, which make up yet
another group of transfection agents53 (compare Table 1).
After an introduction of the different transfection and transduc-
tion possibilities one may ask what is the best choice for a partic-
ular gene-transfer requirement. Some special cases have already
been mentioned above. A general recommendation is difﬁcult,
however in Figure 2 we suggest an initial decision tree that might
be helpful for two approaches: (i) researchers aiming for a gene
transfer may get recommendations to chose their method and (ii)
researchers developing new transfection agents may use the
guideline in a reverse mode to place their method in the right con-
text of applications.
However, the ﬂow chart in Figure 2 is only a rough classiﬁcation
and a particular application may need deviations or even re-evalu-
ation. An example for a very unusual procedure is the genetic
manipulation of erythrocytes. Because these cells have no protein
translation mechanism54, gene transfer needs to be performed in
precursor cells (preferably by Lentiviral transduction), which then
need to be differentiated into red blood cells.55
Novel transfection reagents should be compared to well-estab-
lished methods, which are mostly commercially available kits or
procedures. However, this comparison makes only sense when
comparing to known agents. ‘Magic’ mixtures of unknown coposi-
tion of some suppliers (see above) do not qualify as standards and
therefore references are limited.
Evaluating new gene transfer methods is usually based on sev-
eral parameters, starting with the efﬁciency of the gene transfer
(transfection rate; onset and duration of expression) and survival
rate of the transfected/transduced cells (viability).
It is worthwhile to mention that in addition to the transfection
method itself, there are numerous strategies to increase transfec-
tion efﬁciency and gene expression. One concept is to minimize
the lysosomal degradation of the DNA by deactivation of DNAse
activity in the lysosomes, for example, by chloroquine.56 Another
option is to favour the active chromatin formation, for example,
by sodium butyrate.
When it comes to gene transfer as a therapeutic method addi-
tional properties that need to be considered include safety aspects
such as the speciﬁcity of the gene transfer into the target cells to
avoid unwanted expression and adverse effects in other cell types.
Another issue is the extent of the expression, because very high lev-
els of expression often cause additional problems such as the occur-
rence of unspeciﬁc cellular responses to the overexpression.
Therefore not only the induction of gene expression, but also its ter-
mination needs to be solved/adjustable in order to create a success-
ful gene therapy.Acknowledgments
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